NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $45.00 target price on the stock.

Several other research analysts have also recently commented on NRXP. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research note on Monday, April 27th. D. Boral Capital reissued a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reissued a “buy” rating and issued a $10.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, August 18th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock traded up $0.10 during trading hours on Tuesday, reaching $3.55. 401,911 shares of the company’s stock were exchanged, compared to its average volume of 1,136,410. The company has a market cap of $153.76 million, a P/E ratio of -6.45 and a beta of 2.18. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The company’s 50 day moving average is $3.74 and its two-hundred day moving average is $3.02.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.33 million. As a group, analysts predict that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ethos Financial Group LLC increased its position in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the period. Global Retirement Partners LLC bought a new position in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $107,000. Two Sigma Investments LP lifted its position in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares in the last quarter. State Street Corp raised its stake in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares in the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter valued at $318,000. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.